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Abstract 
Objectives: Age has a plausible but not independently established prognostic influence in 
multiple sclerosis (MS). Its relationship with long term disability accumulation remains to be 
fully elucidated.  
Methods: Kaplan Meier analysis and binary logistic regression models investigated the 
effect of age at disease onset, age at onset of progression and of current age on attainment 
of severe disability levels (DSS 6-8-10) among 1023 from the London Ontario database.  
Results: Older age at relapsing-remitting (RR) phase onset, independent of disease 
duration and early relapse frequency, was associated with higher risk of attaining hard 
disability status scale (DSS) levels. This was secondary to increased risk of conversion to 
secondary progressive (SP) MS. Onset at age 40 (OR = 4.22) and at age 50 (OR = 6.04) 
respectively, doubled and tripled the risk of developing SP vs. onset at age 20 (OR = 2.05). 
Younger age of conversion to SP MS associated with shorter times to DSS levels from 
disease onset. However unexpectedly, the progressive course was unaffected by age at RR 
onset and only modestly affected by age at SP onset. Median ages at attainment of DSS 6 
were strikingly similar among PP and RR/SP patients (49 vs. 48 years; p = 0.05), DSS 8 (58 
vs. 58 years; p = 0.44) and DSS 10 (78 vs. 78 years; p = 0.63).  
Conclusions: Development of SP is the dominant determinant of long term prognosis, very 
largely independent of disease duration and early relapse frequency. Age is an independent 
factor in disability development, primarily acting on probability and latency of SP onset. 
 
Keywords: Multiple Sclerosis; Relapses; Age; Long term disability; Natural history. 
Abbreviations: MS = multiple sclerosis; RR = relapsing remitting; SP = secondary 
progressive; PP = primary progressive; DSS = disability status scale, OR = odds ratio. 
Word and illustrations count: Summary 259 words; main text 2959 words; 3 tables; 2 
figures. 
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Introduction 
Clinical features of Multiple Sclerosis (MS) are heterogeneous, with severity ranging from 
benign 1, 2 to malignant 3.  In relapsing remitting (RR) MS, despite modest predictive effects 
of early relapses 4-7, total attacks during the RR phase do not detectably influence time to 
requiring walking aid or worse 7. Conversion to secondary progressive (SP) MS is the key 
determinant of long term prognosis 7. The progressive phase leading to development of 
severe disability, is homogeneous among the progressive subtypes of the disease (SP and 
primary progressive [PP] MS) 8, evolves largely independent of factors preceding it  5, 7, 8 , 
and may be driven by the same mechanisms leading to its onset 7. 
 
Age has previously been suggested as a factor affecting prognosis in MS patients. Being 
older at disease onset associates with shorter times to disability levels 5, 9-16. Nevertheless, 
this does not apply to PPMS 17, indeed the mean age at onset of progression does not 
significantly differ among all kinds of progressive MS, be it primary or secondary 8, 18, 19. The 
ages at which various disability landmarks are attained have been reported to be similar 
among all MS subtypes 6, 20. In the light of these observations, it has been hypothesized that 
MS could be a single stage disorder driven by neurodegenerative age-related mechanisms 
20. 
 
Against this background we set out to further clarify relationships between age and disease 
evolution before and after the onset of the progressive phase, the key event heralding 
eventual severe disability.  
 
Methods 
The characteristics of the London Ontario MS Clinic have been extensively described 7, 8, 17. 
Patients were evaluated annually or semi-annually. At each visit new information was 
collected and data previously recorded were confirmed. Disability was assessed using the 
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Disability Status Scale (DSS) 21. The observation period spanned from 1972 to 2000 and 
resulted in ascertainment of some 28,000 patient-years. No patient received disease 
modifying therapies (DMTs). The database was recently (2009) subjected to a rigorous data 
quality process. 
 
Population and outcomes 
The London Ontario database comprises 1023 patients with mean disease duration of 24.2 
years. Within the total population two subpopulations were identified: 1) the subgroup from 
Middlesex County (MC) which represented 90% of Middlesex County MS patients 22 2) a 
subgroup of patients seen from disease onset (SO), the vast majority within 12 months from 
the diagnosis 23. Survival between the two subgroups and the total population is remarkably 
similar (data unpublished) indicating minimal ascertainment and referral bias affecting data. 
The disease spectrum included: 1) RR-MS; 2) SP-MS, following an initial relapsing-remitting 
phase; 3) PP-MS, having progressive onset 17. Progressive relapsing (PR) cases were 
included in the PP group as the two groups have been shown to have the same long term 
outcome 24. Progressive disease, both in PP and SP cases, was defined by at least 1 year of 
continuous deterioration, regardless of the rate of worsening. Transitory plateaus and trivial 
temporary improvements in the relentlessly progressive course were recorded in the long 
term, although steady progression was the rule. Clinical onset was derived from the date 
(year) of first symptom; for patients not seen at onset, DSS scores 21 were determined 
retrospectively from outside records. Documentation collected for the onset of the SP phase 
and for the hard disability endpoints of requiring aid for walking (DSS 6), restriction to bed 
with preserved use of arms (DSS 8), which were the focus of this study, and death from MS 
(DSS 10) were repeatedly checked during the observation period thus resolving ambiguities 
over time. If DSS scores had not been recorded, they were derived from the description of 
neurological findings only when unambiguous which was nearly universally the case for cane 
and bedridden status.  
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Statistical methods 
We investigated the relationships among disability accumulation and the following variables: 
1) age at disease onset, 2) age at onset of progression, 3) current age (age at last 
assessment) and 4) type of disease course.  
Binary logistic regression analysis was utilized to assess: 1) the risk of experiencing a PP 
course according to increasing age at disease onset, 2) the risk of entering the SP phase 
and to attain DSS levels according to increasing age at disease onset, increasing current 
age (“growing older”) and increasing disease duration and 3) the risk of attaining DSS levels 
according to increasing age at onset of progression. Within each disease course category 
patients were grouped according to age at disease onset and age at onset of progression. 
Grouping aimed for similar numbers in each category; additional stratifications served as 
internal controls.  
Kaplan-Meier analysis estimated times to conversion to SP from disease onset and from 
birth (age at onset of progression) and the times to attain DSS 6-8-10 from disease onset, 
from onset of SP and from birth (age at disability levels) in each group. Log-rank test 
investigated differences observed. Information on DSS assessment was not always 
available resulting in different numbers of patients contributing at each DSS level when 
estimating the time to disability survival curves. Patients who had not yet reached given DSS 
levels but who had been followed for a known period were right censored. Cox regression 
multiple analysis investigated the concomitant predictive effect of age and number of 
relapses. In addition it was also used for internal validation of results from binary logistic 
regression analysis. The Chi-squared test and the Wilcoxon signed-rank test were used for 
the comparisons of categorical data and quantitative data, respectively. Spearman’s rank 
correlation test assessed the effect of age on number of relapses experienced. 
 
A statistical analysis plan was set up and mutually agreed among the authors 25. All 
statistical analyses were performed using SPSS software (version 15) by one author (AS) 
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and subsequently independently recalculated at the Sylvia Lawry Centre where R software 26 
was used.   
 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study received institutional review board ethical approval, and written informed consent 
was obtained from all patients (or guardians of patients) participating in the study.  
 
 
Results 
Within the total population, 806 patients had relapsing onset (78.8%) and 217 (21.2%) had 
PP MS (Table 1). By the end of the observation period, among relapsing remitting patients, 
272 (33.7%) remained in the RR phase and 534 (66.3%) had entered the SP phase. PP vs 
RR/SP group had less female preponderance (57.1% vs 68.8%; p = 0.001), was a decade 
older at disease onset (mean age 38.6 vs 28.5 years; p < 0.001) and presented more 
frequently with motor disturbances (44.7% vs 17.9%; p < 0.001).  
 
The number of patients reaching disability endpoints increased with disease duration and in 
greater proportion within the PP group compared to the RR onset group. Ten years after 
clinical onset, 63.9 % of PP patients vs. only 26.1% of RR/SP patients had already reached 
DSS 6 and 21.1% vs 8.8% had reached DSS 8; at 20 years these percents increased to 
91.8 % vs 53.1% reaching DSS 6 and 56.2% vs 27.3% reaching DSS 8, respectively. By the 
end of the observation period 79% of PP patients had reached DSS 8; 48% of relapsing 
onset patients was distributed between DSS 8 and 10. 
  
PP patients took significantly shorter estimated times to disability endpoints from clinical 
onset (Table 1). However, the two groups matched more closely, with less than 3 years 
7 
 
difference on average for reaching DSS 6-8, when survival was compared from DSS 3, 
thereby encompassing the SP phase 7 for most (but by no means all) RR patients. 
 
Age and disability accumulation  
Age at disease onset 
The risk of having a PP disease course increased with age at onset (HR 1.10 per additional 
year at onset; p < 0.001). However, age at disease onset within the PP group had no 
influence on disease evolution 17. In contrast, age at onset of RR phase impacted on the 
long term disease evolution by affecting probability and latency of the progressive course. 
Being older proportionally increased the probability of entering the SP phase (OR = 1.04; p < 
0.001) and of reaching DSS 6 (OR 1.04; p < 0.001), DSS 8 (OR 1.02; p = 0.02) and DSS 10 
(OR 1.03; p = 0.004). Onset at age 40 (OR = 4.22) and at age 50 (OR = 6.04) respectively 
doubled and tripled the risk of converting to SP MS, compared to onset at the age of 20 (OR 
= 2.05) (Figure 1). These effects appeared independent as they remained unchanged when 
adjusted for the concomitant effect of disease duration.  
 
When grouped, RR patients younger at first relapse took significantly longer to convert to SP 
MS and to accumulate severe disability (Table 2) from disease onset. This effect was limited 
to the evolution of the RR phase and was no longer evident once the progressive phase 
supervened. Times to attain disability endpoints from onset of secondary progression were 
remarkably similar among groups (Table 2).  
 
Multiple analysis  
The number of relapses in the first two years (early relapses) 7 and age at onset exerted 
their predictive effect primarily by increasing the probability of converting to SP MS and by 
shortening the latency to onset of the progressive phase. Therefore, we tested whether age 
at onset of the RR phase conditioned early relapse frequency. Surprisingly, age at first 
symptom did not significantly affect the number of early relapses (r = -0.05, p = 0.13). In 
8 
 
contrast, being older at onset correlated with significantly fewer relapses experienced from 
the 3rd year up to onset of the SP phase (r = -0.26, p < 0.001). In addition, multiple Cox 
regression analysis demonstrated that the predictive effects of year 1-2 relapse frequency 
and of age at first relapse are independent. Those younger at onset of the relapsing 
remitting phase had a lower hazard both of entering the progressive phase and of reaching 
DSS levels, independent of the number of early relapses. 
 
Age at onset of progression 
Type of disease course did not significantly influence the age at which progression 
developed. Survival analysis from birth to onset of progression demonstrated that the mean 
age when entering the progressive phase was similar in those with an initial RR course (i.e. 
SP MS) or not (PP MS) (40.2 vs 38.6 years; p = 0.096) (Table 1). Age at onset of SP 
inversely correlated with the probability of reaching DSS levels. Being older at conversion to 
SP MS significantly decreased the risk of attaining DSS 6 (OR 0.96; p = 0.03) and DSS 8 
(OR 0.96; p < 0.001). Groups younger at SP entry took significantly shorter times to DSS 
levels from disease onset (Table 3). However, times to attain disability levels from onset of 
progression were largely uninfluenced by the age at which SP developed. Only those aged ≤ 
30 at conversion to SP attained DSS 8 from progression in significantly shorter time (Table 
3). 
 
Current age  
We next investigated the relationship between patients’ current age (age at last visit) and 
disability accumulation. In the total population ageing significantly increased the probability 
of reaching DSS 3 (OR 1.08; p < 0.001), DSS 6 (OR 1.07; p < 0.001) DSS 8 (OR 1.04; p < 
0.001) and marginally DSS 10 (OR 1.01; p = 0.05). The regression model, adjusted for the 
concomitant effect of current age and disease duration, left the impact of growing older 
unchanged while the effect of disease duration became insignificant for all endpoints (DSS 3 
OR = 1.02, p = 0.19; DSS 6 OR = 1.01, p = 0.59; DSS 8 OR = 1.01, p = 0.53) except for 
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DSS 10 (OR = 0.97, p = 0.002). These results strongly indicate that disability accumulates 
while growing older independently of the duration of disease.  
 
However, there were significant differences in the effects of current age between the 
relapsing- and the progressive-onset groups. In RR onset patients, ageing significantly 
increased the probability of entering the SP phase (OR 1.06; p < 0.001) and of attaining DSS 
3 (OR 1.08; p < 0.001), DSS 6 (OR 1.06; p < 0.001) and DSS 8 (OR 1.04; p < 0.001),  all 
independently of disease duration. In striking contrast, current age did not exert any effect on 
the likelihood of reaching disability endpoints in PP patients (DSS 3 OR = 0.93, p = 0.48; 
DSS 6 OR = 1.01, p = 0.70; DSS 8 OR = 1.02, p = 0.27; DSS 10 OR = 0.98, p = 0.12). 
 
Age at disability landmarks 
The percent of patients reaching DSS levels necessarily increased proportionally with age; 
the rate at which disability accumulated while growing older was very similar between PP 
and SP patient groups. By age 55, 70.9% of PP patients and 74.7% of SP patients had 
reached DSS 6; by age 65, these percents increased to 89.4% and 85.9% respectively.  
 
The type of initial disease course did not exert any statistically significant effect on the age at 
which disability levels were reached. Relapsing onset and progressive onset patients 
attained DSS 3, 6, 8 and 10 at remarkably similar ages (Figure 2). 
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Discussion 
This study provides, perhaps for the first time, a complete account of mean/median ages at 
all milestone disability levels in a large well ascertained population with a long-term follow 
up. Survival analysis from birth estimated for the total population of 1023 patients a mean 
age of 41.6 years (95% CI 40.8 - 42.4) at DSS 3, 49.0 years (95% CI 48.0 - 50.0) at DSS 6, 
58.7 years (95% CI 57.5 - 59.9) at DSS 8 and 75.3 years (95% CI 73.4 - 77.1) at DSS 10. 
Our study redefines age as an independent and significant factor contributing to disease 
evolution and operating on progression probability and latency, now a common theme 
uniting prognostic features.  
 
Age at onset of the RR phase and advancing years (current age) affect disability 
accumulation, independent of disease duration, largely by increasing the probability of 
experiencing a progressive course and by shortening the latency to progression. This is 
further confirmed by the lack of effect of current age on disability accumulation during the PP 
phase, indicating that the impact of growing older on long term outcome in RR patients is 
secondary to the increased probability of converting to SP MS, whilst having relatively little if 
any effect on the evolution of the progressive phase.   
 
Similarly, older age at onset of the RR phase associated with an increased probability and a 
shorter latency to the progressive course and therefore significantly affected the long term 
disease evolution. The risk of converting to SPMS increased proportionally with age at 
onset, independently of number of early relapses. Survival analysis confirmed that groups 
older at RR onset had a shorter latency to progression and consequently took shorter times 
to attain disability endpoints from disease onset. In addition, although relapse frequencies 
overall are strongly age-associated 27, age at onset of the relapsing remitting phase 
surprisingly did not affect early relapse frequency (r = -0.05, p = 0.13). In contrast, older age 
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at onset associated with fewer relapses beyond year 2 (r = -0.26, p < 0.001) due to the 
anticipated onset of the SP phase.  
 
The evolution of the SP phase was confirmed to be largely independent of factors preceding 
its onset 5, 7, 8. Times to DSS levels from onset of SP were similar among patients grouped 
according to age at disease onset, indicating that the slope of the secondary progressive 
phase was not much affected by age at which the RR phase started. However the 
anamnestic nature of SP does not extend to the age of its onset. Patients with a worse 
outcome had a shorter relapsing remitting phase 7 and therefore entered the SP phase at 
younger age. Groups younger when converting to SPMS were at higher risk of developing 
severe disability and took significantly shorter times to attain endpoints from disease onset 
(Table 3) but the size of this effect is seen in the small difference in odds ratios for DSS 6 
(OR 0.96; p = 0.03) and DSS 8 (OR 0.97; p = 0.003). These results emphasize the key role 
played by the onset of the progressive phase on the long term evolution and confirm that 
outcome is mainly determined before becoming progressive.  
 
However, the rate of disability accumulation during progression not only was unaffected by 
age at onset of RR phase but was also found to be not influenced by age at onset of 
progression nor by ageing. PP and SP started at similar ages and their similar evolution led 
all patients to accumulate disability at similar ages (Figure 2). Accordingly, though in mild 
contrast with a previous report 20, (which, it must be said, had a frequency of right-censored 
patients exceeding 50%), Kaplan Meier-estimated times from birth to disability landmarks 
were not affected by type of initial disease course (Figure 2).  
 
These findings imply that the progressive phase may be the core phenotype of MS, and its 
probability, latency, and slope should be the essential targets of treatment and investigation 
alike. Prognosis is confirmed to be largely determined before the onset of progression and 
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age appears to have a strong effect on the evolution of the RR phase. Elucidation of 
mechanisms is beyond the capacity and scope of the present study but there are immediate 
implications not only for prognosis in all types of MS, but also for clinical trials design and 
treatment strategy. Broad age ranges (e.g. 18-55 years) being commonly recruited in clinical 
trials may add unanticipated variation which may weaken randomization schemes. 
Stratification by age, heretofore underutilized, may be perceived to be advantageous, 
especially if the primary outcome is onset of SP. Early disease stages, especially during 
young age, represent a window of opportunity for future treatments which should be focused 
on preventing or delaying the onset of the secondary progression, the major determinant of 
permanent disability development 
. 
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Tables 
 
Table 1: Clinical and demographic features of PP and RR/SP patients 
  Relapsing onset Progressive onset  p values 
No of patients 806 (272 RR/534 SP) 217  
No of males 252 (31.2%) 93 (42.9%) 0.002* 
No of females 554 (68.8%) 124 (57.1%)  
Sex ratio (F/M) 2.19 1.33   
Disease duration 
Mean years (± SD) 24.4  (± 10.1) 23.7 (± 9.2) 0.676** 
Median years 23 23   
Age at onset       
Mean years (± SD) 28.5 (± 8.9) 38.6 (± 10.3) < 0.001** 
Median years 27 40   
Age at onset of progression 
Mean years (± SD) 40.2 (±  10.0) 38.6 (± 10.3) 0.096*** 
Median years  39 40   
Age at last assessment  
Mean years (± SD) 53.0 (± 12.9) 62.2 (± 12.1) <0.001** 
Median years  52 63   
Systems involved at onset 
Motor  145 (18.0%) 97 (44.7%) < 0.001* 
Sensory 438 (54.3%) 80 (36.9%) < 0.001* 
Cerebellar  51 (6.3%) 10 (4.6%) 0.342 * 
Brainstem  167 (20.7%) 11 (5.1%) < 0.001* 
Optic 174 (21.6%) 10 (4.6%) < 0.001* 
Bowel/bladder 25 (3.1%) 7 (3.2%) 0.926* 
Number of symptoms at onset 
1 535 (66.4%) 142 (65.4%) 0.245* 
> 1 262 (32.5%) 73 (33.6%)  
Unavailable 9 2   
Kaplan Meier estimates mean years [95% CI] from disease onset to disability levels                                        
(% not reaching the endpoint) 
DSS 6 21.2 years [19.8-22.6] (30.5%) 9.5 years [8.5-10.6] (2.3%) < 0.001*** 
DSS 8 30.9 years [29.1-32.8] (49.3%) 20.5 years [18.6-22.3] (20.7%) < 0.001*** 
DSS 10 48.2 years [5.8-50.6] (81.5%) 35.3 years [32.8-37.8] (68.2%) < 0.001*** 
Kaplan Meier estimates mean years [95% CI] from DSS 3 to disability levels                                    
DSS 6  7.9 years [7.2-8.5] 5.1 years [4.4-5.8]  < 0.001*** 
DSS 8   17.6 years [16.3-19.0]    15.3 years [13.9-16.7]  0.03*** 
DSS 10  32.0 years [30.0-34.0]    27.6 years [25.9-29.2]  0.30*** 
SD: standard deviation. *Chi-square test; ** Wilcoxon rank test; *** Log Rank test.  
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Table 2: Kaplan Meier survival analysis of RR/SP patients stratified according to age at MS onset. Mean 
(median) times from MS onset to onset of SP and to disability endpoints and from DSS 3 to disability endpoints  
  Kaplan Meier estimated times from disease onset to 
Age at onset 
of RR phase  
n of 
patients 
SP  p  DSS 6 p   DSS 8 p  DSS 10 p 
≤ 20 145 25.8 (22) < 0.001 25.6 (25) < 0.001 34.8 (34) 0.001 56.0 (63) 0.002 
21-30 371 20.2 (16) < 0.001 21.5 (19) < 0.001 31.1 (29) 0.007 44.9 (-) 0.036 
> 30* 285 15.3 (10)   16.8 (14)   26.1 (25)   39.7 (42)   
  Kaplan Meier estimated times from onset of progression to 
        DSS 6 p  DSS 8 p  DSS 10 p  
≤ 20       5.0 (2) 0.27 13.9 (11) 0.11 36.5 (50) 0.56 
21-30    5.0 (3) 0.39 15.3 (12) 0.44 31.9 (30) 0.91 
> 30*       5.5 (4)   15.0 (13)   28.2 (28)   
*Reference category. P values obtained through comparison with reference category (Log Rank Test).  
 
Table 3: Kaplan Meier survival analysis of SP patients stratified according to age at onset of progression. Mean 
(median) times to disability endpoints from disease onset and from onset of progression.  
    Kaplan Meier estimated times from disease onset to 
Age at onset of 
SP phase  
n of 
patients  
DSS 6 p DSS 8 p DSS 10 p 
≤ 30 90 9.8 (8) < 0.001 17.1 (13) < 0.001 44.0 (63) 0.001 
31-45 264 14.8 (14) < 0.001 25.1 (23) 0.002 42.9 (-) 0.02 
> 45* 155 20.3 (18)   31.3 (29)   44.9 (45)   
    Kaplan Meier estimated times from onset of progression to  
    DSS 6 p DSS 8 p  DSS 10 p 
≤ 30   4.6 (2) 0.06 11.4 (7) 0.001 34.5 (50) 0.91 
31-45  5.2 (3) 0.44 15.3 (13) 0.76 29.3 (33) 0.80 
> 45*   5.5 (4)   14.7 (15)   26.6 (27)   
*Reference category. P values obtained through comparison with reference category (Log Rank Test).  
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Figure legends 
Figure 1: Risk of converting to SP MS according to age at onset of RR phase 
Binary Logistic regression analysis. Odd ratios (OR) expressing the risk of converting to secondary 
progressive (SP) MS according to increasing age at onset of relapsing remitting (RR) phase. The 
probability of entering the SP phase increases proportionally with the age at onset. 
Figure 2: Ages at attainment of disability endpoints according to type of disease 
course  
Kaplan Meier survival analysis from birth. Mean (median) age at onset of progression (OPP) and at 
disability levels in RR/SP and PP patients. P values obtained with Log Rank test.  
 
 
 
 
 
Figures 
Figure 1: Binary Logistic regression analysis. Risk (odds ratios = OR) of converting to secondary progressive (SP) 
MS according to increasing age at onset of relapsing remitting (RR) phase.  
 
 
 
 
 
 
 
 
Figure 2: Kaplan Meier survival analysis from birth. Mean (median) age at onset of progression (OPP) and at 
disability levels in RR/SP and PP patients.  
 
P values obtained through Log Rank test.  
 
 
 
